Measurement of HbA1c with a new phase function using RBC phase image from a low-cost digital holographic microscopy.

IF 2.1 4区生物学 Q3 BIOTECHNOLOGY & APPLIED MICROBIOLOGY

Biotechnology Letters Pub Date : 2025-06-23 DOI:10.1007/s10529-025-03610-7

Ashok Kumar Sahu, Bandita Panda, Adik Amiyan Tripathy, Sandip Kumar Dash, Atanu Kumar Bal, Naba Kishor Sahoo, Sukanta Kumar Tripathy

{"title":"Measurement of HbA1c with a new phase function using RBC phase image from a low-cost digital holographic microscopy.","authors":"Ashok Kumar Sahu, Bandita Panda, Adik Amiyan Tripathy, Sandip Kumar Dash, Atanu Kumar Bal, Naba Kishor Sahoo, Sukanta Kumar Tripathy","doi":"10.1007/s10529-025-03610-7","DOIUrl":null,"url":null,"abstract":"Objective: Development of a new phase function for measuring HbA1c, using a low-cost digital holographic microscopy to monitor the glucose level in diabetes.Results: Here, we propose a new parameter, <math><msub><mtext>Ø</mtext> <mrow><mi>cp</mi></mrow> </msub> </math> based on two different phases of RBCs, one, the absolute phase at the center, <math><msub><mtext>Ø</mtext> <mi>c</mi></msub> </math> and the other, the average phase at the periphery, <math><msub><mtext>Ø</mtext> <mi>p</mi></msub> </math> . The <math><msub><mtext>Ø</mtext> <mrow><mi>cp</mi></mrow> </msub> </math> value varied almost linearly (R2 = 0.952) with HbA1c (%) in the blood. We used a low-cost digital holographic microscope (DHM) to record the hologram of RBCs, followed by digital reconstruction with the help of our newly introduced code. The critical value of <math><msub><mtext>Ø</mtext> <mrow><mi>cp</mi></mrow> </msub> </math> at 3.5 was found to be equivalent to 6.5% HbA1c in high-performance liquid chromatography (HPLC), beyond which indicates hyperglycemia.Conclusion: The method can be used for large-scale and low-cost estimation of HbA1c (%) with <math><msub><mtext>Ø</mtext> <mrow><mi>cp</mi></mrow> </msub> </math> of ≥ 3.5.","PeriodicalId":8929,"journal":{"name":"Biotechnology Letters","volume":"47 4","pages":"65"},"PeriodicalIF":2.1000,"publicationDate":"2025-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biotechnology Letters","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.1007/s10529-025-03610-7","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: Development of a new phase function for measuring HbA1c, using a low-cost digital holographic microscopy to monitor the glucose level in diabetes.

Results: Here, we propose a new parameter, $Ø_{cp}$ based on two different phases of RBCs, one, the absolute phase at the center, $Ø_{c}$ and the other, the average phase at the periphery, $Ø_{p}$ . The $Ø_{cp}$ value varied almost linearly (R² = 0.952) with HbA1c (%) in the blood. We used a low-cost digital holographic microscope (DHM) to record the hologram of RBCs, followed by digital reconstruction with the help of our newly introduced code. The critical value of $Ø_{cp}$ at 3.5 was found to be equivalent to 6.5% HbA1c in high-performance liquid chromatography (HPLC), beyond which indicates hyperglycemia.

Conclusion: The method can be used for large-scale and low-cost estimation of HbA1c (%) with $Ø_{cp}$ of ≥ 3.5.

查看原文本刊更多论文

利用低成本数字全息显微镜的RBC相位图像，用新的相位函数测量HbA1c。

目的：利用低成本的数字全息显微镜监测糖尿病患者的血糖水平，建立一种新的测量糖化血红蛋白的相位函数。结果：本文提出了一个新的参数Ø cp，该参数基于红细胞的两个不同相位，一个是中心的绝对相位Ø c，另一个是外围的平均相位Ø p。Ø cp值与血中HbA1c（%）几乎呈线性关系（R2 = 0.952）。我们使用低成本的数字全息显微镜（DHM）来记录红细胞的全息图，然后在我们新引入的代码的帮助下进行数字重建。在高效液相色谱（HPLC）中发现，临界值Ø cp在3.5时相当于6.5%的HbA1c，超过该值即为高血糖。结论：该方法可用于HbA1c（%）的大规模、低成本估算，Ø cp≥3.5。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Biotechnology Letters 工程技术-生物工程与应用微生物

CiteScore

5.90

自引率

3.70%

发文量

108

审稿时长

1.2 months

期刊介绍： Biotechnology Letters is the world’s leading rapid-publication primary journal dedicated to biotechnology as a whole – that is to topics relating to actual or potential applications of biological reactions affected by microbial, plant or animal cells and biocatalysts derived from them. All relevant aspects of molecular biology, genetics and cell biochemistry, of process and reactor design, of pre- and post-treatment steps, and of manufacturing or service operations are therefore included. Contributions from industrial and academic laboratories are equally welcome. We also welcome contributions covering biotechnological aspects of regenerative medicine and biomaterials and also cancer biotechnology. Criteria for the acceptance of papers relate to our aim of publishing useful and informative results that will be of value to other workers in related fields. The emphasis is very much on novelty and immediacy in order to justify rapid publication of authors’ results. It should be noted, however, that we do not normally publish papers (but this is not absolute) that deal with unidentified consortia of microorganisms (e.g. as in activated sludge) as these results may not be easily reproducible in other laboratories. Papers describing the isolation and identification of microorganisms are not regarded as appropriate but such information can be appended as supporting information to a paper. Papers dealing with simple process development are usually considered to lack sufficient novelty or interest to warrant publication.